Sai Parenteral's
SAIPARENTNSE

Sai Parenteral's

₹540.85-2.55 (0.47%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
539.00
Today’s high
546.20
52 week low
400.00
52 week high
706.00
Open price
546.15
Previous close
543.40
Live volume
58,240
Lower circuit
434.75
Upper circuit
652.05

Fundamentals

Market Cap
₹2,398Cr
ROE
2.91%
P/E Ratio(TTM)
115.49
EPS(TTM)
4.70
P/B Ratio
4.89
Dividend Yield
0.00%
Industry P/E
37.23
Book Value
111.09
Debt to Equity
0.68
Face Value
5

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹182
-9.16%
Profit (Cr)
₹7.92
-39.82%
-75075150225
Jun '25
Dec '25
Mar '26
Jun '26

About

Sai Parenterals is a diversified pharmaceutical formulations company. While it started as a specialist in "parenterals" (injectables), it has evolved into a multi-dosage platform. Its business is split into two main verticals:Branded Generic Formulations and CDMO (Contract Development and Manufacturing). The company covers high-growth therapeutic areas such as cardiovascular, anti-diabetic, neuropsychiatry, and oncology. It operates five manufacturing facilities—four in Hyderabad (Telangana) and one in Ongole (Andhra Pradesh).;
CEO/MD
Anil Kumar Karusala
Founded in
2001
NSE symbol
SAIPARENT

Shareholding pattern

Sep '25
Mar '26
Apr '26
Jun '26
Shareholder details
Livesquawk
SAI Parenterals' Q1 EBITDA surged to ₹235M from ₹47M YoY. Q1 EBITDA margin declined to 13.2% from 14.2% YoY.
Livesquawk
Sai Parenterals schedules analyst and investor meeting on July 2. The meeting will focus on company updates and future outlook.
Livesquawk
Sai Parenterals plans FY27 capex: ₹118 Cr for India expansion, EU-GMP upgrades. AUD 53 Mn for Australia's largest pharma plant, ₹18 Cr for R&D center.
2026
11
Aug
Quarterly Result
Release date
23
May
Quarterly & Annual Result
Release date
Events calendar
View upcoming events in other stocks